Phaseline

Companies › CastleVax

CastleVax: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NDV-HXP-S-KP.2
Newcastle Disease Virus-based mucosal vaccine expressing SARS-CoV-2 spike protein (KP.2 va
–Phase 2COVID-19–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07215520NDV-HXP-S-KP.2Phase 2COVID-19Infectious diseaseSep 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Medicago Brii Biosciences Eveliqure Biotechnologies Sanaria SIGA Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.